On January 11, Changchun High-tech (000661) announced that the company recently received a notice from Jin Lei, a shareholder holding more than 5% of the shares, and learned that Jin Lei and Wang Simian had gone through the procedures for dissolving their marriage by agreement and made arrangements for the division of shares. 
It is worth noting that in this divorce incident, the woman obtained a ** worth more than 4 billion yuan, and became the second largest shareholder of Changchun High-tech. Jin Lei has previously cashed out about 5.2 billion yuan.
*Times E Company reporter noted that before the change in equity, Jin Lei held Changchun High-tech 3464570,000 shares, accounting for 856%, Wang Simian does not hold Changchun high-tech shares. According to the divorce agreement signed by the two parties, Jin Lei intends to transfer his holdings of Changchun High-tech 3001410,000 shares (about 742%), which was divided into Wang Simian's name. According to January 11, Changchun High-tech 13341 yuan share price calculation, 3001The market value of 410,000 shares corresponds to more than 4 billion yuan. After this equity change, Jin Lei still holds Changchun High-tech 463160,000 shares, the proportion of shares held in listed companies has been sharply reduced to 114%, no longer a shareholder holding more than 5% of the shares; Wang Simian will hold Changchun High-tech 3001410,000 shares, jumping to become the second largest shareholder of the listed company. 
It is worth noting that after the completion of the share split, Jin Lei and Wang Simian will calculate the identity of shareholders together, and the provisions of the "Implementation Rules" on the proportion of shareholders will be applied to the merger. That is, shareholders who continue to share more than 5% of the shares, no more than 1% of the quota for any 90 consecutive natural days through centralized auction transactions, and no more than 2% of the quota for any 90 consecutive natural days through block trading, and respectively fulfill the pre-disclosure obligations of shareholders holding more than 5% of the shares through centralized auction transactions. Back in December 2020, a reporter from **Times E Company noticed that during 2020 and 2021, Jin Lei had accumulated nearly 5.2 billion yuan in Changchun High-tech. According to the disclosure of Changchun High-tech Announcement, Jin Lei accumulated 4.09 million shares of the company through centralized bidding and block trading from July 10, 2020 to December 16, 2020, accounting for 1 of the company's total share capital0106%；On December 16, 2020, Changchun High-tech traded 15700 million yuan block transaction, with a turnover of 390 yuan shares and a trading volume of 4.03 million shares. From December 22, 2020 to May 20, 2021, Jin Lei accumulated **Changchun High-tech 809320,000 shares, accounting for 19997%；Combined with the bulk transaction data of the year, rough statistics show that Jin Lei's cash amount this time is 358.6 billion yuan. 
In response to this change, Changchun High-tech said that the above matters will lead to changes in the company's shareholders' equity, but will not lead to changes in the actual controller of the listed company, and will not involve a change in the company's control. At present, Wang Simian does not hold any position in a listed company or participate in the production, operation and management of Changchun High-tech except for Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as Jinsai Pharmaceutical), a subsidiary of Changchun High-tech Holdings. Therefore, Changchun High-tech believes that the change in equity has no substantial impact on the company's operation and management, and there is no harm to the interests of listed companies and other shareholders. He is currently the general manager of Kinsey Pharmaceutical.
Changchun High-tech is known as the "Northeast Medicine Mao", and its existing pharmaceutical products cover many pharmaceutical subdivisions such as innovative genetic engineering pharmaceuticals, new vaccines, modern Chinese medicine, etc., and has built five business platforms integrating genetic engineering drug platform, biological vaccine platform, antibody platform, chemical pharmaceutical platform and Chinese patent medicine platform of its subsidiaries. In 2019, Changchun High-tech passed asset restructuring and made a price of 563.7 billion yuan won the 29th of Jinsai Pharmaceutical5% of the shares, the proportion of the latter increased to 995%。As the founder of Jinsai Pharmaceutical, Jin Lei currently holds the remaining 05% of the shares, and served as the director and general manager of Kinsey Pharmaceutical. According to the data, Jinsai Pharmaceutical was established in 1997, the company is the only genetic engineering new drug incubation base in the country in the national "Eleventh Five-Year Plan" new drug creation major project, China's first genetic engineering drug quality management demonstration center, the world's only genetic engineering pharmaceutical company with PEG-based long-acting growth hormone, and also a world-renowned biopharmaceutical company in the field of children's and women's health. For Changchun High-tech, the position of Jinsai Pharmaceutical is extremely important. In 2022, Changchun High-tech will achieve an operating income of 1262.7 billion yuan, with a net profit of 41400 million yuan. Among them, Jinsai Pharmaceutical achieved revenue of 1021.7 billion yuan, and the net profit attributable to the parent company was 421.7 billion yuan. In the first half of 2023, Changchun High-tech will achieve an operating income of 616.8 billion yuan, net profit of 216 billion yuan; Kinsey Pharmaceutical's revenue was 513.9 billion yuan, net profit of 219.7 billion yuan. At present, Jinsai Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production and sales of genetically engineered biological drugs, and its main products are human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection), follicle-stimulating hormone for injection, triptorelin acetate injection, cetrorelix acetate for injection, and human granulocyte macrophage stimulating factor gel for external use, covering assisted reproduction, child growth, women's health, and elderly health. Products at all stages of the life cycle. 
Editor-in-charge: Peng Bo Proofreader: Wang ChaoquanThese, users are watchingST Daji has received 6 one-word daily limits in a row! The concept of supply and marketing cooperatives has risen again; This provincial medical insurance news! The maternal and infant plates are boiling.
Fosun, continue to sell, sell, sell!
It's set! The first A-share delisted stock in 2024.
The epitome of Zhejiang businessmen in "Flowers": In the 90s, the old clothing company really asked Fei Xiang to endorse it.
Good start! Listed companies frequently sign large orders at the beginning of the year
Welcome to scan the code**e company app
First-hand informationFrontline interactionsOne-click publishingSettled in the capital circleA little little hands, a new experience! ▲